People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

A simple urine test was found to detect prostate cancer with greater accuracy than the standard PSA (prostate-specific ...

Prostate cancer is a leading cause of cancer-related death among men in the United States. Despite this, widespread adoption ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy. Find an average timeline here.

Right now, there are more than 250 generic drugs on the market that show potential for fighting cancer, even though they were ...

Prostate cancer is the most commonly diagnosed cancer in men worldwide, accounting for more than 1.4 million new cases each ...

Clinicians worldwide regard (Pluvicto) as a significant breakthrough therapy for patients with advanced disease' ...

They are more prone to metastasis and drug resistance ... to develop more tailored – and more effective – prostate cancer treatments. Further, chimeric RNA isn’t just found in prostate ...

AI-derived predictive biomarker identifies two thirds of patients with high-risk prostate cancer who may benefit from ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

Dr. David Carlson, Nuclear Medicine Physician, Ridley-Tree Cancer Center and Dr. William Pace, Nuclear Medicine Physician, Ridley-Tree Cancer Center. (courtesy photo) The Ridley-Tree Cancer Center ...